drugset
drugset / Trial / NCT06007677

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677 ↗

Phase 2 Active not recruiting 56 enrolled Astria Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.

Timeline

Start
2023-09-26
Primary completion
2031-03
Completion
2031-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Navenibart Monoclonal antibody — Subcutaneous

Indications

hereditary angioedema